Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Remo Panaccione, Robert H. Riddell et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
SCENIC International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel DiseaseLoren Laine, Yu‐Xiao Yang, Tonya Kaltenbach et al.|Gastroenterology|2015Cited by 765
SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel diseaseLoren Laine, Yu‐Xiao Yang, Tonya Kaltenbach et al.|Gastrointestinal Endoscopy|2015Cited by 408
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Remo Panaccione et al.|The Lancet|2022Cited by 383
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic ResectionMiguel Regueiro, Pierre Desreumaux, Brian G. Feagan et al.|Gastroenterology|2016Cited by 329